Kidney Watch: 19 June 2026

Tolerance induction without irradiation, a European paediatric immunosuppression guideline, DSA risk clustering, and evidence against routine procurement biopsy headline this week’s kidney transplant literature.
kidney
weekly briefing
Published

June 19, 2026

AI-generated summary. Verify each item against the source before relying on it.

This issue is anchored by immunological tolerance and immunosuppression: a phase 1/2a trial combining donor bone marrow with recipient regulatory T cells achieved donor chimerism without irradiation and allowed three of six recipients to reach belatacept monotherapy, while a new European guideline consolidates immunosuppressive practice after paediatric kidney transplantation. Two papers sharpen risk assessment and surveillance — unsupervised clustering of donor-specific antibodies stratified DSA-positive recipients into clinically distinct risk groups, and an integrated diffusion-MRI/biomarker model showed promise for triaging the diagnostic “gray zone” before biopsy. Deceased-donor utilisation features strongly: a national OPTN analysis argues that procurement biopsy in functionally normal donors drives discard and ischaemic delay without improving outcomes. The remaining papers address access and system performance — a randomised trial of living-donor wage reimbursement, a real-world cost comparison of pre-emptive transplantation versus dialysis, and a long-run registry analysis showing that kidney transplantation retains the largest and most persistent unmet need across solid organs. Together they span tolerance, rejection-risk stratification, donor utilisation, and equitable access — the recurring pressure points of UK transplant practice.

1. Donor bone marrow together with recipient regulatory T cells induces chimerism without irradiation in kidney transplantation

Wekerle T, Muckenhuber M, Heinzel A, Weijler AM, David AF, Kainz V, Hu K, Mucha J, Mengrelis K, Reindl-Schwaighofer R, Böhmig GA, Watschinger B, Györi G, Soliman T, Salat A, Schwarz C, Muhm M, Heinze G, Wolzt M, Worel N, Fortschegger M, Lion T, Regele H, Berlakovich G, Halloran PF, Edinger M, Oberbauer R. Sci Transl Med, 2026. PMID: 42308328.

This controlled phase 1/2a trial (NCT03867617) tested whether chimerism-based tolerance could be induced in HLA-mismatched living-donor kidney transplantation without the recipient irradiation that limited earlier protocols. Six study patients received polyclonal recipient regulatory T cells together with donor bone marrow cells immediately after transplantation, under an immunosuppression backbone of thymoglobulin, belatacept, sirolimus, steroids, and short-course tocilizumab; the control group received none of the cell products or tocilizumab. Total leukocyte donor chimerism was detected in every study patient and in none of the controls, meeting the primary endpoint of higher chimerism in the study group (reported p = 0.001). Chimerism appeared across multiple lineages, reaching up to 4% within T cells. In three of the six study patients, immunosuppression could be reduced to belatacept monotherapy. Antidonor reactivity was diminished in in-vitro T-cell proliferation assays, and T-cell-receptor sequencing showed dampened expansion of antidonor clones, suggesting donor-specific downmodulation rather than global immunosuppression. The authors frame this strictly as proof of concept, and the sample of six patients with limited follow-up precludes any claim about durable tolerance or graft survival. For UK living-donor programmes the appeal is a tolerance strategy that avoids irradiation, but the approach remains experimental and far from routine adoption.

2. Evidence- and Consensus-based European Guideline for Immunosuppressive Therapy After Pediatric Kidney Transplantation

Grünewald A, Ahlenstiel-Grunow T, Arslan Z, Battelino N, Bot Rachisan AL, Bouts A, Busutti M, Cornelissen E, de Jong H, Dudley J, Düzova A, Eibensteiner F, Fichtner A, Fomina S, Gonzalez ML, Gulhan B, Grabitz C, Hogan J, Höcker B, Jeruschke S, Kanzelmeyer N, Kim JJ, Korst U, Labbadia R, Litwin M, Marks S, Melk A, Novljan G, Obrycki L, Oh J, Pape N, Pasini A, Patry C, Pohl M, Preka E, Prytula A, Rieger S, Schiffer M, Schild R, Seeman T, Stojanovic J, Testa S, Tönshoff B, Torres DD, Weber LT, Nothacker M, Pape L. Transplantation, 2026. PMID: 42308432.

This multi-society European guideline addresses the longstanding problem that immunosuppression after paediatric kidney transplantation rests on a thin evidence base, producing highly variable international practice and inconsistent uptake of individualised, newer-agent strategies. It was developed between January 2024 and December 2025 following the methodological manual of the German Association of Scientific Medical Societies, with input from the German societies for paediatric nephrology, nephrology, transplantation and paediatrics, the German Kidney Association, the International Pediatric Transplant Association, the European Society for Paediatric Nephrology, and the Cooperative European Paediatric Renal Transplant Initiative. The authors present it as a state-of-the-art set of recommendations grounded in the best available evidence supplemented by formal consensus. They emphasise that the formal consensus process carries particular weight where evidence is weak, inconclusive, or absent, with several recommendations resting on expert opinion alone. Because it is a consensus document, it reports no trial statistics, and clinicians should read the full text to gauge the strength of each individual recommendation. For UK paediatric transplant units it offers a contemporary European reference point that may help harmonise immunosuppressive protocols and support the adoption of individualised regimens.

3. Immunologic clustering of donor-specific antibodies and clinical outcomes in kidney transplant recipients

Al-Qurashi SH, Khalil MAM, Mahmood HHK, Alsharif MM, Alqurashi YF, Alghamdi L, Al-Ghamdi RA, Alsaedi ZA, Cruz AJD, Sadagah NM. World J Transplant, 2026. PMID: 42281880.

This single-centre retrospective study set out to refine immunological risk assessment in DSA-positive recipients, on the premise that conventional descriptors such as DSA class and mean fluorescence intensity (MFI) fail to capture the multidimensional nature of risk. Of 260 kidney transplants performed at King Fahad Armed Forces Hospital in Saudi Arabia, 151 recipients were DSA-positive, and 112 with complete immunological and follow-up data underwent unsupervised k-means clustering. The clustering variables were DSA class, number of DSA, cumulative MFI, early graft function (eGFR at four months), and HLA mismatch. Three distinct clusters emerged: a high-risk group (n = 58) combining Class I and II DSA with high antibody numbers and MFI, and the worst outcomes (acute rejection 6.9%, graft loss 6.9%, mortality 5.2%); an intermediate-risk group (n = 34) with predominantly Class II DSA and moderate MFI; and a low-risk group (n = 20) with isolated Class I DSA, low antibody burden, and excellent early graft function. Principal component analysis showed clear separation between the three groups, and the gradient of immunological burden tracked early post-transplant outcomes. The findings are limited by small numbers, a single centre, retrospective design, and short follow-up, so the thresholds should not yet guide practice. Nonetheless, the work signals that data-driven, multidimensional DSA profiling could eventually help UK units tailor monitoring and immunosuppression beyond MFI cut-offs alone.

5. Rethinking procurement biopsy in donors with normal renal function: A barrier to kidney utilization without survival benefit

Sibulesky L, Kaufman DM, Bakthavatsalam R, Leca N, Perkins JD. World J Transplant, 2026. PMID: 42281884.

This national study used Organ Procurement and Transplantation Network data from 2014–2024 to ask whether procurement biopsy adds value in deceased-donor kidneys with preserved function (terminal eGFR ≥ 60 mL/min/1.73 m²). Among 158,365 recovered kidneys, 46.6% were biopsied, and biopsied kidneys were more than six times as likely to be discarded (28.2% vs 4.4%); biopsy findings alone accounted for discard of 5.9% of biopsied kidneys, more than half of which showed only minimal histological abnormalities. In a propensity-matched cohort of 52,094 transplants (26,047 per arm) with excellent covariate balance, a centre-clustered Cox model found biopsy associated with higher death-censored graft failure (HR 1.12, 95% CI 1.05–1.19). Biopsy prolonged cold ischaemia time by roughly 42 minutes and raised delayed graft function (30.6% vs 27.6%); sequential attenuation showed cold ischaemia and delayed graft function together explained about 55% of the survival association, pointing to a process-related rather than biological mechanism. The absolute effect was small — restricted mean survival time fell by about 0.03 years (≈12 days) at five years — and decision-curve analysis showed no added net benefit from biopsy beyond standard clinical variables. As an observational registry analysis it cannot establish causation and reflects US practice, but the convergence of methods is persuasive. For UK practice it reinforces a more selective, function-led approach to procurement biopsy that could lift utilisation of otherwise transplantable kidneys.

6. Effects of Donor Wage Reimbursement: Findings From the Living Donor Lost Wages Randomized Trial

Rodrigue JR, Fleishman A, Schold JD, Pavlakis M, Evenson AR, Duncan S, Mandelbrot DA, Baliga PK. Transplantation, 2026. PMID: 42308433.

This randomised trial tested whether reimbursing donor lost wages would increase living-donor kidney transplantation (LDKT), reasoning that financial loss deters both candidates and potential donors. Patients undergoing transplant evaluation were randomised to a maximum wage reimbursement of either $1,500 or $3,000 and encouraged to discuss the programme within their social networks, then compared with matched historical controls using multivariable logistic regression. In the primary analyses, access to any reimbursement was not significantly associated with LDKT (adjusted OR 0.85, 95% CI 0.39–1.85, p = 0.68) or with having at least one donor evaluated within a year (adjusted OR 1.07, 95% CI 0.76–1.50, p = 0.70). The reimbursement level made no difference either, with no significant contrast between the $1,500 and $3,000 caps. An exploratory analysis that extended follow-up to account for COVID-related shutdowns did associate reimbursement with higher odds of LDKT (adjusted OR 2.16, 95% CI 1.12–4.18, p = 0.02), hinting that effects may emerge over longer horizons. The authors conclude that wage reimbursement at these levels was insufficient on its own to expand living donation, with the historical-control design and pandemic disruption as key caveats. For the UK, where removing financial disincentives to donation is an active policy lever, the message is that reimbursement likely needs to sit within a broader support package rather than stand alone.

7. Real-world economic comparison of preemptive kidney transplant vs maintenance dialysis in patients with end-stage kidney disease

Schold JD, Potukuchi P, Voss J, Preblick R, Sienko D, Yu T, Noshad S, Boame N, Devlin A. J Med Econ, 2026. PMID: 42318627.

This retrospective observational study compared healthcare resource use and costs between pre-emptive kidney transplantation (transplantation without prior dialysis) and maintenance dialysis using Optum’s Clinformatics Data Mart Database from January 2012 to July 2024. Among 14,135 patients with end-stage kidney disease (1,153 pre-emptive transplant, 12,982 maintenance dialysis), outcomes at 24 months were compared with weighted generalised linear modelling. Transplant recipients were far more likely to be hospitalised (OR 10.68, 95% CI 6.00–19.02) and had more hospitalisations per person (event-rate ratio 1.21), reflecting the perioperative burden, but they had fewer emergency department visits (OR 0.49) and fewer outpatient visits per person (event-rate ratio 0.30). Costs for pre-emptive transplantation were higher initially, but dialysis costs overtook them from roughly month five onward. Over 24 months, estimated total per-person costs were $303,725 for pre-emptive transplantation versus $637,134 for dialysis, a saving of $333,409 (95% CI $263,461–$403,356). The analysis is limited by its observational design and the likelihood that pre-emptively transplanted patients are systematically healthier, and the absolute dollar figures reflect the US payer system. Even so, it adds economic weight to the clinical case for pre-emptive transplantation, a priority the UK already promotes through earlier listing and living donation.